AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37466151 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (losartan 50 mg)
Number of subjects: 9379
Study 37466213 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 61
Study 37466213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 37466221 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A/Hong Kong/125/2017 (H7N9) MIV
Number of subjects: 304
Study 37466221 — intervention group
Group type: COMPARATOR
Intervention: Unadjuvanted A/Hong Kong/125/2017 (H7N9) MIV
Number of subjects: 304
Study 37466280 — intervention group
Group type: EXPERIMENTAL
Intervention: MIND diet with mild caloric restriction
Number of subjects: 604
Study 37466280 — intervention group
Group type: COMPARATOR
Intervention: Control diet with mild caloric restriction
Number of subjects: 604
Study 37466374 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 0
Study 37466374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37466379 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic cervicovestibular rehabilitation program (education, home exercises, manual techniques, sub-symptom threshold aerobic exercise [STAE] program)
Number of subjects: 41
Study 37466379 — intervention group
Group type: COMPARATOR
Intervention: Telerehabilitation program (education, home-exercises, STAE program without manual techniques)
Number of subjects: 41
Study 37466456 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention during venipuncture
Number of subjects: 0
Study 37466456 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group) during venipuncture
Number of subjects: 0
Study 37466566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with paclitaxel associated with systemic chemotherapy
Number of subjects: 30
Study 37466690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral LI4 acupuncture prior to IUD insertion
Number of subjects: 72
Study 37466690 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 72
Study 37466938 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos with Black speakers
Number of subjects: 2904
Study 37466938 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos with physician presenters
Number of subjects: 2904
Study 37466938 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos about prostate cancer screening
Number of subjects: 2904
Study 37466938 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos with patient presenters
Number of subjects: 2904
Study 37466938 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos about clinical trials
Number of subjects: 2904
Study 37466938 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos with Black presenters
Number of subjects: 2904
Study 37466951 — intervention group
Group type: COMPARATOR
Intervention: Non-MGD
Number of subjects: 69
Study 37466951 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate MGD
Number of subjects: 69
Study 37466951 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe MGD
Number of subjects: 69
Study 37466983 — intervention group
Group type: EXPERIMENTAL
Intervention: CXA-UP
Number of subjects: 200
Study 37466983 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 200
Study 37467018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to reduce bioaerosol exposure (specific details not provided)
Number of subjects: 673
Study 37467018 — intervention group
Group type: EXPERIMENTAL
Intervention: Health examinations and questionnaires (specific details not provided)
Number of subjects: 673
Study 37467018 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory analyses (specific details not provided)
Number of subjects: 673
Study 37467018 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis (specific details not provided)
Number of subjects: 673
Study 37467030 — intervention group
Group type: EXPERIMENTAL
Intervention: UM171-expanded CB
Number of subjects: 137
Study 37467119 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab
Number of subjects: 14
Study 37467119 — intervention group
Group type: COMPARATOR
Intervention: FVIII products
Number of subjects: 14
Study 37467119 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14
Study 37467180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 4545
Study 37467180 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin plus non-absorbable disaccharide
Number of subjects: 4545
Study 37467180 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable disaccharides
Number of subjects: 4545
Study 37467213 — intervention group
Group type: COMPARATOR
Intervention: Lumicitabine (single loading dose then 9 maintenance doses)
Number of subjects: 0
Study 37467213 — intervention group
Group type: COMPARATOR
Intervention: Lumicitabine (40/20 mg/kg, 60/40 mg/kg LD/MD twice-daily for 5 days)
Number of subjects: 0
Study 37467213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37467227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (potassium rich diets, potassium supplements, and mineralocorticoid receptor antagonists (MRA) for six months)
Number of subjects: 14
Study 37467227 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 37467243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Personal Sound Amplification Products (PSAPs)
Number of subjects: 28
Study 37467243 — intervention group
Group type: COMPARATOR
Intervention: No PSAPs (Control)
Number of subjects: 28
Study 37467318 — intervention group
Group type: EXPERIMENTAL
Intervention: GDA-201 (NK cells expanded ex vivo with IL-15 and NAM) combined with rituximab
Number of subjects: 19
Study 37467318 — intervention group
Group type: EXPERIMENTAL
Intervention: GDA-201 (NK cells expanded ex vivo with IL-15 and NAM)
Number of subjects: 19
Study 37467348 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bonding technique with an additional layer of compomer adhesive at the molar/tube interface.
Number of subjects: 30
Study 37467348 — intervention group
Group type: COMPARATOR
Intervention: Conventional bonding technique.
Number of subjects: 30
Study 37467452 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and temozolomide
Number of subjects: 22
Study 37467454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician nudge
Number of subjects: 2146
Study 37467454 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2146
Study 37467454 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient only nudge
Number of subjects: 2146
Study 37467454 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and clinician nudge
Number of subjects: 2146
Study 37467458 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-cancer detection test using a targeted methylation assay and machine learning classifiers
Number of subjects: 3508
Study 37467458 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-cancer detection test
Number of subjects: 3508
Study 37467497 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 vaccine (various formulations)
Number of subjects: 0
Study 37467497 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS6 vaccine (most immunogenic formulation)
Number of subjects: 0
Study 37467497 — intervention group
Group type: COMPARATOR
Intervention: Naturally acquired anti-CPS IgG
Number of subjects: 0
Study 37467498 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilebesiran (10, 25, 50, 100, 200, 400, or 800 mg)
Number of subjects: 107
Study 37467498 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilebesiran (≥200 mg)
Number of subjects: 107
Study 37467498 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilebesiran (800 mg) under high-salt diet conditions
Number of subjects: 107
Study 37467498 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilebesiran (800 mg) coadministered with irbesartan
Number of subjects: 107
Study 37467498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 37467628 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital preoperative screening (n=200)
Number of subjects: 400
Study 37467628 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face screening (n=201)
Number of subjects: 400
Study 37467930 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg q3w; 16 cycles)
Number of subjects: 1005
Study 37467930 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 1005
Study 37467930 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (in stage II-IIIA PD-L1 TC ≥1%)
Number of subjects: 1005
Study 37467930 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (in stage II-IIIA PD-L1 TC ≥50%)
Number of subjects: 1005
Study 37467936 — intervention group
Group type: EXPERIMENTAL
Intervention: Physio-EndEA
Number of subjects: 31
Study 37467936 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 37468045 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (56 days at levels 1.2 to 2.6 times the Recommended Dietary Allowance)
Number of subjects: 0
Study 37468045 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol isotope dilution (RID)
Number of subjects: 0
Study 37468045 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-predicted TBS
Number of subjects: 0
Study 37468045 — intervention group
Group type: COMPARATOR
Intervention: Healthy peers (control group)
Number of subjects: 0
Study 37468185 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Revascularization (CR)
Number of subjects: 1641
Study 37468185 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete Revascularization (ICR)
Number of subjects: 1641
Study 37468185 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (CON)
Number of subjects: 1641
Study 37468217 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-standard inhaler names
Number of subjects: 1150
Study 37468530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 0
Study 37468530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37468570 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-model group (FIT + risk factors including age, sex, smoking status, and CRC family history)
Number of subjects: 22748
Study 37468570 — intervention group
Group type: COMPARATOR
Intervention: FIT-only group
Number of subjects: 22748
Study 37468569 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (first-line treatment)
Number of subjects: 191
Study 37468569 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (de novo MBC)
Number of subjects: 191
Study 37468569 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (≥ second-line treatment)
Number of subjects: 191
Study 37468569 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (overall cohort)
Number of subjects: 191
Study 37468569 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (adverse events)
Number of subjects: 191
Study 37468652 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) navigation system
Number of subjects: 8
Study 37468652 — intervention group
Group type: COMPARATOR
Intervention: Standard CT-guided bone biopsy (Control)
Number of subjects: 8
Study 37468652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AR and Control)
Number of subjects: 8
Study 37468685 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Degludec (IDeg)
Number of subjects: 3225
Study 37468751 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Total Gastrectomy (OTG)
Number of subjects: 96
Study 37468751 — intervention group
Group type: COMPARATOR
Intervention: Minimally Invasive Total Gastrectomy (MITG)
Number of subjects: 96
Study 37468836 — intervention group
Group type: EXPERIMENTAL
Intervention: High genetic risk score (GRS) (≥ 3)
Number of subjects: 192
Study 37468836 — intervention group
Group type: COMPARATOR
Intervention: Low genetic risk score (GRS) (0-2)
Number of subjects: 192
Study 37468859 — intervention group
Group type: EXPERIMENTAL
Intervention: RFID localization technique
Number of subjects: 40
Study 37468859 — intervention group
Group type: COMPARATOR
Intervention: Hook wire localization (gold-standard)
Number of subjects: 40
Study 37468890 — intervention group
Group type: EXPERIMENTAL
Intervention: North Star Ambulatory Assessment (NSAA)
Number of subjects: 61
Study 37468890 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI2)
Number of subjects: 61
Study 37468890 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI3)
Number of subjects: 61
Study 37468898 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent coaching via telerehabilitation (video conferencing)
Number of subjects: 200
Study 37468898 — intervention group
Group type: COMPARATOR
Intervention: Standard care (in-clinic parent coaching)
Number of subjects: 200
Study 37468918 — intervention group
Group type: EXPERIMENTAL
Intervention: Human umbilical cord blood-MSCs
Number of subjects: 34
Study 37468918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 37468932 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 37468932 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0
Study 37468932 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 37468932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 37468932 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall predictive cut-off value
Number of subjects: 0
Study 37468932 — intervention group
Group type: EXPERIMENTAL
Intervention: <5% reduction in PANSS total score
Number of subjects: 0
Study 37468932 — intervention group
Group type: EXPERIMENTAL
Intervention: <10% decrease in PANSS total score
Number of subjects: 0
Study 37468978 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE) combined with Cognitive Behaviour Therapy (CBT) for 15 weeks of PE and 10 weeks of CBT
Number of subjects: 4
Study 37468987 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-Time Delphi (RTD)
Number of subjects: 222
Study 37468987 — intervention group
Group type: COMPARATOR
Intervention: Multi-Round Delphi (MRD)
Number of subjects: 222
Study 37469099 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 37469099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37469291 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving recompensation after alcohol abstinence
Number of subjects: 204
Study 37469291 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abstinence
Number of subjects: 204
Study 37469757 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning
Number of subjects: 60
Study 37469757 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-learning
Number of subjects: 60
Study 37469757 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-learning with expert feedback
Number of subjects: 60
Study 37469757 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 37470057 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy and anti-PD-L1 (atezolizumab)
Number of subjects: 50
Study 37470101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiperstat 2.5 mg
Number of subjects: 660
Study 37470101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiperstat 5 mg
Number of subjects: 660
Study 37470101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study 37470137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Vorinostat (DL1: 100 mg, DL2: 200 mg)
Number of subjects: 52
Study 37470295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg every 8 weeks (q8w)
Number of subjects: 2992
Study 37470295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg every 8 weeks (q8w)
Number of subjects: 2992
Study 37470295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg q8w
Number of subjects: 2992
Study 37470379 — intervention group
Group type: EXPERIMENTAL
Intervention: nCT
Number of subjects: 2211
Study 37470379 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT
Number of subjects: 2211
Study 37470445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remdesivir (200 mg followed by 100 mg daily for 5 days)
Number of subjects: 131
Study 37470445 — intervention group
Group type: COMPARATOR
Intervention: No study drug (control)
Number of subjects: 131
Study 37470678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored music listening; details on dosage and duration not available
Number of subjects: 0
Study 37470678 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not available
Number of subjects: 0
Study 37470718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (≥3 daily insulin injections/insulin pump therapy)
Number of subjects: 1441
Study 37470772 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on age, waist circumference, systolic blood pressure, glycated hemoglobin, antihypertensive medication use, and early onset preeclampsia (yes/no)
Number of subjects: 1397
Study 37470772 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional predictors used in the prediction model
Number of subjects: 1397
Study 37470840 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated bilateral theta-burst stimulation (TBS) consisting of 5 sequential bilateral intermittent TBS (600 pulses) and continuous TBS (600 pulses) daily for 5 days at 120% resting motor threshold.
Number of subjects: 25
Study 37470840 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated bilateral theta-burst stimulation (TBS)
Number of subjects: 25
Study 37470901 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 99
Study 37470901 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 99
Study 37470901 — intervention group
Group type: COMPARATOR
Intervention: Warm water
Number of subjects: 99
Study 37470901 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (warm water, decaffeinated coffee, caffeinated coffee)
Number of subjects: 99
Study 37470969 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE surgery using the 500-kHz Visumax laser platform
Number of subjects: 444
Study 37470969 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ORA
Number of subjects: 444
Study 37471052 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV+ infants (n = 29, 12%)
Number of subjects: 249
Study 37471052 — intervention group
Group type: COMPARATOR
Intervention: CMV- infants
Number of subjects: 249
Study 37471052 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV+ infants
Number of subjects: 249
Study 37471089 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention with exercise, cognitive training, and vitamin D (arm 1)
Number of subjects: 175
Study 37471089 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise, cognitive training, and placebo vitamin D (arm 2)
Number of subjects: 175
Study 37471089 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise, sham cognitive training, and vitamin D (arm 3)
Number of subjects: 175
Study 37471089 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise, sham cognitive training, and placebo vitamin D (arm 4)
Number of subjects: 175
Study 37471089 — intervention group
Group type: COMPARATOR
Intervention: Control group with balance-toning exercise, sham cognitive training, and placebo vitamin D (arm 5)
Number of subjects: 175
Study 37471115 — intervention group
Group type: EXPERIMENTAL
Intervention: wMammogram intervention (mobile web app)
Number of subjects: 122
Study 37471115 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational brochure)
Number of subjects: 122
Study 37471115 — intervention group
Group type: EXPERIMENTAL
Intervention: wMammogram intervention
Number of subjects: 122
Study 37471117 — intervention group
Group type: EXPERIMENTAL
Intervention: Polybactum (PLGG) administered for 3 cycles followed by a 1-month follow-up period without treatment.
Number of subjects: 55
Study 37471122 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I delivered via Noctem COAST and CPP-led deprescribing
Number of subjects: 50
Study 37471135 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARThealth Pregnancy intervention
Number of subjects: 200
Study 37471135 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (control)
Number of subjects: 200
Study 37471145 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-SPE
Number of subjects: 340
Study 37471280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stent (RES) system
Number of subjects: 50
Study 37471452 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring electrodes replaced every 12 hours
Number of subjects: 66
Study 37471452 — intervention group
Group type: COMPARATOR
Intervention: Monitoring electrodes replaced every 24 hours
Number of subjects: 66
Study 37471574 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection followed by adjuvant treatment (standard arm)
Number of subjects: 218
Study 37471574 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy only (experimental arm)
Number of subjects: 218
Study 37471590 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg every 2 weeks for 16 weeks, followed by 12 weeks of sarilumab or placebo
Number of subjects: 15
Study 37471590 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 37471590 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg
Number of subjects: 15
Study 37473602 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering education on nutrition impact side effects
Number of subjects: 83
Study 37473602 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 83
Study 37473746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric Oxyhydroxide (SFOH) 1,500 mg iron/day
Number of subjects: 286
Study 37473746 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer Carbonate 2.4 g/day
Number of subjects: 286
Study 37473848 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE postpartum depression prevention program
Number of subjects: 2320